Education
About Us
Working with TipRanks
Follow Us
Renalytix (GB:RENX)
LSE:RENX
RENX Stock Chart & Stats
Day’s Range― - ―
52-Week Range6.50p - 23.10p
Previous CloseN/A
Volume11.59K
Average Volume (3M)62.45K
Market Cap
$27.32M
Enterprise ValueN/A
Total Cash (Recent Filing)$9.63M
Total Debt (Recent Filing)$8.21M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Jun 17, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding331,206,020
10 Day Avg. Volume75,569
30 Day Avg. Volume62,446
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-7.57
Price to Sales (P/S)0.00
P/FCF Ratio-1.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Renalytix News
PremiumCompany Announcements
Renalytix PLC Sees Major Shareholder Shift with UBS Acquisition
PremiumCompany Announcements
UBS Reduces Holdings in Renalytix Below 5%
PremiumCompany Announcements
UBS Group AG Acquires Significant Stake in Renalytix PLC
PremiumCompany Announcements
Renalytix PLC Sees Change in Major Shareholder Holdings
PremiumCompany Announcements
UBS Group AG Acquires Significant Stake in Renalytix
PremiumCompany Announcements
Renalytix Achieves Milestone with 20% Revenue Growth in Q3PremiumCompany Announcements
UBS Reduces Holdings in Renalytix PLC Below 5% Threshold---
Options Prices
Currently, No data available
---
Ownership Overview
16.10% Insiders
―
Mutual Funds
0.05% Other Institutional Investors
83.86% Public Companies and
Individual Investors
RENX FAQ
What was Renalytix’s price range in the past 12 months?
Renalytix lowest share price was 6.50p and its highest was 23.10p in the past 12 months.
What is Renalytix’s market cap?
Renalytix’s market cap is $27.32M.
When is Renalytix’s upcoming earnings report date?
Renalytix’s upcoming earnings report date is Jun 17, 2025 which is in 31 days.
How were Renalytix’s earnings last quarter?
Renalytix released its earnings results on Mar 18, 2025. The company reported -0.038p earnings per share for the quarter, missing the consensus estimate of N/A by -0.038p.
Is Renalytix overvalued?
According to Wall Street analysts Renalytix’s price is currently Overvalued.
Does Renalytix pay dividends?
Renalytix does not currently pay dividends.
What is Renalytix’s EPS estimate?
Renalytix’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Renalytix have?
Renalytix has 331,206,020 shares outstanding.
What happened to Renalytix’s price movement after its last earnings report?
Renalytix reported an EPS of -0.038p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Renalytix?
Currently, no hedge funds are holding shares in GB:RENX
---
Company Description
Renalytix
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.
---
RENX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant strategic achievements, including Medicare coverage developments, inclusion in clinical guidelines, successful fundraising, and cost reduction efforts. However, there are challenges such as a decline in revenue and testing volumes, and adoption hurdles in the VA system. The sentiment is balanced, with positive long-term strategic developments countered by short-term operational challenges.Read More>---
RENX Stock 12 Month Forecast
Average Price Target
―Technical Analysis
---